Natera Announces Innovation Roadmap, with Advancements in MRD and Early Cancer Detection
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, will provide an update to the investment community, ...
The American Journal of Managed Care2d
MRD Negativity: A "Robust" Predictor of Survival Outcomes in MM
This meta-analysis sheds more light on the beneficial impact of multiple melanoma (MM) treatments and the predictive value of ...
Hosted on MSN7h
NeoGenomics (NEO) Surges 9.1%: Is This an Indication of Further Gains?
NeoGenomics (NEO) shares ended the last trading session 9.1% higher at $13.78. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This ...
Adaptive Biotech Teams Up With NeoGenomics To Advance MRD Monitoring Options
(RTTNews) - Adaptive Biotechnologies Corp. (ADPT), Tuesday announced a partnership with NeoGenomics, Inc. (NEO), an oncology testing services company, to advance minimal residual disease or MRD ...
The American Journal of Managed Care8d
MRD Status Prior to Allo-HSCT Shows Strong Prognostic Value in AML, MDS
A study demonstrated that pre-transplant measurable residual disease (MRD) status is a strong prognostic factor for overall ...
TipRanks on MSN1d
Adaptive, NeoGenomics partner to expand access to disease monitoring
Adaptive Biotechnologies (ADPT) and NeoGenomics (NEO) announced a multi-year exclusive strategic commercial collaboration ...
Cure Today2d
Always Bring a Second Set of Ears to Your Oncology Checkup!
At my routine oncology checkup, I regretted not bringing my husband when an unexpected medication changes left me feeling ...
一文说清：热门的微小残留病灶（MRD）到底有啥用？
中国肺癌大咖吴一龙教授的团队最近发表了一个很有意思的研究。他们对比了60例 用EGFR靶向药效果非常好的中晚期肺癌患者。他们看起来都一样，用药后都达到了完全缓解，影像学看不出问题，肿瘤标记物也正常，做了一次MRD检查也是阴性。
Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients
Adaptive Biotechnologies Corporation (Nasdaq:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and ...
Tongue cancer organoids reveal secrets of chemotherapy resistance
Oral cancer is an increasingly prevalent disease worldwide, with over 300,000 new cases diagnosed each year. Among oral ...
微小残留病灶（MRD）：癌症个性化治疗的新希望
（二）微小残留病灶检测的基本理念是监测体内是否存在少量癌细胞。了解是否有残留的癌细胞至关重要，因为它直接影响到复发和后续治疗的决策。若确实存在明显的癌细胞，判断相对容易；但在少量残留的情况下，传统影像学方法如CT扫描或肿瘤标记物检测的灵敏度不足，往往难以发现少量残留的细胞。